United Arab Emirates — Emirates Drug Establishment
Tracked across 3 events · 18 articles · First seen Dec 20, 2025 · Last active Aug 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: The United Arab Emirates — Emirates Drug Establishment announced the approval of Onasemnogene abeparvovec, demonstrating its commitment to providing patients with advanced genetic therapies and positioning the United Arab Emirates as a regional hub for pharmaceutical innovation.
Dec 20, 2025 · 6 articles
Regulatory
Impact: The United Arab Emirates — Emirates Drug Establishment approved Semaglutide (semaglutide) for long-term weight management, reaffirming its commitment to promoting the pharmaceutical ecosystem and addressing obesity challenges.
Jun 01, 2026 · 6 articles
Regulatory
Impact: The United Arab Emirates — Emirates Drug Establishment granted the approval, positioning itself as a forward-thinking regulator and facilitating patient access to a novel oral treatment.
Aug 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track United Arab Emirates — Emirates Drug Establishment live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard